Clinical trial
A Phase 2, Randomized, Multicenter, Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
NCT06668805 is registered in ClinicalTrials.gov with BioMarin Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Multicenter, Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
- Lead sponsor
- BioMarin Pharmaceutical
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- November 22, 2024
- Completion date
- September 30, 2041
- Enrollment
- 30 (estimated)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.